NCT02222428View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

July 31, 2009

Conditions
Healthy
Interventions
DRUG

BI 1744 CL/BI 54903 XX FDC

DRUG

BI 54903 XX

DRUG

BI 1744 CL

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY